Leukomed® Sorbact® Resources

Surgical site infections (SSIs) are of serious concern for clinicians, patients and healthcare institutions worldwide. This study evaluated a new wound management pathway using Leukomed® Sorbact® (Essity) post-operative wound dressings in women with raised body mass index (BMI) undergoing lower uterine segment caesarean section (LUSCS) in the NHS Wrightington Wigan and Leigh Foundation Trust. Previous practice indicated use of a standard postoperative dressing for women with a BMI <35 and PICO™ single-use negative pressure wound therapy (NPWT) dressing for women with a BMI >35, following surgery. The new wound management pathway indicated that Leukomed Sorbact was suitable for women with a BMI ≥30–<50, gestational diabetes mellitus (GDM) or previous caesarean section with complications; NPWT dressings continued to be used for women with BMI ≥50, type 1 diabetes, previous numerous caesarean sections or at high risk of infection. Questionnaires were devised and disseminated for clinician and patient groups in relation to dressing use and patient satisfaction with the dressing.

Surgical site infections (SSIs) are the most common type of nosocomial infection, accounting for up to 20% of all hospitalacquired infections in Europe (European Centre for Disease Prevention and Control [ECDPC], 2013). There are varying SSI rates reported across the UK. In 2016, Public Health Wales reported an overall 14-day SSI rate for women undergoing caesarean section of 4.35% — 83% of which were superficial infections and 92.5% were detected after discharge (PHW, 2016). From 2015–2016, Aneurin Bevan University Health Board (ABUHB) services experienced an increase in the SSI rate for women birthing by caesarean section from 3.07% to 5.86% respectively. Therefore, a multifaceted approach to quality improvement (ABUHB organisational method) was adopted throughout the duration of 2017, with a view to implement by 2018. The aim was to reduce SSIs for women birthing by caesarean section in ABUHB. Interventions included the use of evidence-based practice and guidelines, education and engagement among clinicians, patients and staff, and the gradual implementation of Leukomed^® Sorbact^® (Essity) post-operative dressings.